Sergio A. Quezada

36.4k total citations · 12 hit papers
97 papers, 12.6k citations indexed

About

Sergio A. Quezada is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Sergio A. Quezada has authored 97 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Immunology, 61 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Sergio A. Quezada's work include Cancer Immunotherapy and Biomarkers (43 papers), Immunotherapy and Immune Responses (41 papers) and CAR-T cell therapy research (25 papers). Sergio A. Quezada is often cited by papers focused on Cancer Immunotherapy and Biomarkers (43 papers), Immunotherapy and Immune Responses (41 papers) and CAR-T cell therapy research (25 papers). Sergio A. Quezada collaborates with scholars based in United Kingdom, United States and Denmark. Sergio A. Quezada's co-authors include Karl S. Peggs, James P. Allison, Charles Swanton, Randolph J. Noelle, Tyler R. Simpson, Elizabeth M. Jaffee, Solange Peters, Mark Yarchoan, Timothy A. Chan and Albrecht Stenzinger and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Sergio A. Quezada

93 papers receiving 12.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

2018 1.8k citations Charles Swanton, Sergio A. Quezada et al. profile →
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

2013 1.1k citations Tyler R. Simpson, Fubin Li et al. The Journal of Experimental Medicine profile →
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

2015 825 citations Sergio A. Quezada et al. profile →
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

2009 726 citations Karl S. Peggs, Sergio A. Quezada et al. The Journal of Experimental Medicine profile →
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

2017 662 citations Samra Turajlic, Kevin Litchfield et al. profile →
Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism

2005 661 citations Sergio A. Quezada et al. profile →
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

2010 635 citations Sergio A. Quezada, Tyler R. Simpson et al. The Journal of Experimental Medicine profile →
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

2006 554 citations Sergio A. Quezada profile →
CD40/CD154 Interactions at the Interface of Tolerance and Immunity

2004 513 citations Sergio A. Quezada et al. profile →
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

2006 337 citations Karl S. Peggs, Sergio A. Quezada et al. profile →
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

2014 229 citations Xiaozhou Fan, Sergio A. Quezada et al. The Journal of Experimental Medicine profile →
Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma

2021 222 citations Giulia Agliardi, Anna Rita Liuzzi et al. Nature Communications profile →

Peers

Countries citing papers authored by Sergio A. Quezada

Since Specialization

Citations

This map shows the geographic impact of Sergio A. Quezada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio A. Quezada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio A. Quezada more than expected).

Fields of papers citing papers by Sergio A. Quezada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergio A. Quezada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio A. Quezada. The network helps show where Sergio A. Quezada may publish in the future.

Co-authorship network of co-authors of Sergio A. Quezada

This figure shows the co-authorship network connecting the top 25 collaborators of Sergio A. Quezada. A scholar is included among the top collaborators of Sergio A. Quezada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio A. Quezada. Sergio A. Quezada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial. 2024 ·Journal of Clinical Oncology ·Mark Linch, Gianmarco Leone, Yien Ning Sophia Wong, Robert J. Jones, Peter Sankey, Debra H. Josephs, Simon J. Crabb, Louise Harris, Aniqa Tasnim, (unknown), Sergio A. Quezada, Leah Ensell, Anuradha Jayaram, (unknown), Colin C. Pritchard, Alex Freeman, Aiman Haider, Gerhardt Attard, Charles Swanton, Teresa Marafioti	5
2	Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies 2023 ·Journal for ImmunoTherapy of Cancer ·Ernesto López, (unknown), Francesco Nannini, Gordon Weng-Kit Cheung, (unknown), Felipe Gálvez‐Cancino, Sergio A. Quezada, Martin Pulé	33
3	437 Optimised achilles VELOS^TM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer 2023 ·SHILAP Revista de lepidopterología ·Monica Sassi, (unknown), (unknown), (unknown), (unknown), Sarah Thirkell, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Katy Newton, Theres Oakes, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sergio A. Quezada, Edward Samuel	1
4	Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Despoina Karagianni, (unknown), John R. Counsell, Sergio A. Quezada, Emad Moeendarbary, Umber Cheema	8
5	Fcγ receptors and immunomodulatory antibodies in cancer 2023 ·Nature reviews. Cancer ·Felipe Gálvez‐Cancino, (unknown), (unknown), Ignacio Matos, Danwen Qian, Karl S. Peggs, Kevin Litchfield, Sergio A. Quezada	40
6	Breaking the performance ceiling for neoantigen immunogenicity prediction 2023 ·Nature Cancer ·Hugh O’Brien, Max Salm, Laura T. Morton, (unknown), (unknown), (unknown), Pablo D. Becker, Yardena Samuels, Charles Swanton, Marc R. Mansour, Sine Reker Hadrup, Sergio A. Quezada	5
7	Tumor-educated Tregs drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche 2022 ·Cell Reports ·Kevin Kos, Muhammad Assad Aslam, Rieneke van de Ven, Max D. Wellenstein, Wietske Pieters, Antoinette van Weverwijk, Danique E. M. Duits, (unknown), Cheei‐Sing Hau, Kim Vrijland, (unknown), (unknown), Sergio A. Quezada, Rudi Beyaert, Heinz Jacobs, Tanja D. de Gruijl, Karin E. de Visser	39
8	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors 2022 ·Clinical Cancer Research ·(unknown), Yien Ning Sophia Wong, (unknown), Ayse U. Akarca, Pawan Dhami, (unknown), Lucía Conde, Javier Herrero, Olagunju Ogunbiyi, Amir Gander, Tu Vinh Luong, (unknown), Martyn Caplin, Christos Toumpanakis, Karl S. Peggs, Sergio A. Quezada, Teresa Marafioti, Tim Meyer	7
9	Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling 2022 ·Nature Cancer ·Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, (unknown), (unknown), Mansi Shah, Eyal David, (unknown), Oren Barboy, Ignacio Matos, Karl S. Peggs, Sergio A. Quezada, Ido Amit	41
10	Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma breakdown → 2021 ·Nature Communications ·Giulia Agliardi, Anna Rita Liuzzi, Alastair Hotblack, Donatella De Feo, Nicolás Gonzalo Núñez, Cassandra Stowe, Ekaterina Friebel, Francesco Nannini, Lukas Rindlisbacher, Thomas A. Roberts, Rajiv Ramasawmy, (unknown), Bernard Siow, Mark F. Lythgoe, Tammy L. Kalber, Sergio A. Quezada, Martin Pulé, Sònia Tugues, Karin Straathof, Burkhard Becher	222
11	Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma 2020 ·Clinical Cancer Research ·Nouf M. Al‐Rasheed, Lydia Lee, Ehsan Ghorani, Jake Y. Henry, Lucía Conde, (unknown), (unknown), Andrew J.S. Furness, Selina J Chavda, (unknown), (unknown), Oliver C. Cohen, Dominic Patel, Anthony G. Brooks, Manuel Rodriguez‐Justo, Martin Pulé, Javier Herrero, Sergio A. Quezada, Kwee Yong	50
12	The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019 2020 ·Journal for ImmunoTherapy of Cancer ·Paolo A. Ascierto, Carlo Bifulco, (unknown), Claus Garbe, Samir N. Khleif, Jennifer L. McQuade, Kunle Odunsi, Hideho Okada, Chrystal M. Paulos, Sergio A. Quezada, Hussein A. Tawbi, John M. Timmerman, Giorgio Trinchieri, Lisa H. Butterfield, Igor Puzanov	2
13	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity 2020 ·Nature Communications ·Kevin Litchfield, James L. Reading, Emilia L. Lim, Hang Xu, Po Liu, Maise Al-Bakir, Yien Ning Sophia Wong, Andrew Rowan, Samuel A. Funt, Taha Merghoub, David Perkins, Martin Lauss, Inge Marie Svane, Göran Jönsson, Javier Herrero, James Larkin, Sergio A. Quezada, Matthew D. Hellmann, Samra Turajlic, Charles Swanton	68
14	HLA-C restricted neoepitopes contribute significantly to the immune recognition of cancer 2019 ·Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) ·Sofie Ramskov, (unknown), (unknown), Theo Sturm, Annie Borch, Anne-Mette Bjerregaard, (unknown), (unknown), Marco Donia, Rikke Andersen, Arianna Draghi, James L. Reading, Isabel Vogler, Evelyna Derhovanessian, Ulrik Lassen, Uğur Şahin, (unknown), Sergio A. Quezada, Inge Marie Svane, Tim Fugmann, (unknown)	1
15	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus–Derived Vectors Fosters Dendritic Cell–Mediated T-cell Cross-Priming 2018 ·Cancer Research ·Alfonso R. Sánchez-Paulete, Álvaro Teijeira, José I. Quetglas, María E. Rodríguez-Ruiz, Álvaro Sánchez-Arráez, Sara Labiano, Iñaki Etxeberría, Arantza Azpilikueta, Elixabet Bolaños, (unknown), Noëlia Casares, Sergio A. Quezada, Pedro Berraondo, David Sancho, Cristian Smerdou, Ignacio Melero	69
16	TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors 2016 ·Cancer Research ·Laurie Menger, Anna Śledzińska, Katharina Bergerhoff, Frederick Arce Vargas, Julianne Smith, Laurent Poirot, Martin Pulé, Javier Herrero, Karl S. Peggs, Sergio A. Quezada	62
17	Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure 2015 ·Cancer Research ·Alex Miranda, Juan M. Funes, (unknown), (unknown), (unknown), Sergio A. Quezada, Rolando Pérez, (unknown)	4
18	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma breakdown → 2013 ·The Journal of Experimental Medicine ·Tyler R. Simpson, Fubin Li, Welby Montalvo-Ortiz, Manuel A. Sepúlveda, Katharina Bergerhoff, Frederick Arce, Claire Roddie, Jake Y. Henry, Hideo Yagita∥, Jedd D. Wolchok, Karl S. Peggs, Jeffrey V. Ravetch, James P. Allison, Sergio A. Quezada	1093
19	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts breakdown → 2010 ·The Journal of Experimental Medicine ·Sergio A. Quezada, Tyler R. Simpson, Karl S. Peggs, Taha Merghoub, Jelena Vider, Xiaozhou Fan, Ronald G. Blasberg, Hideo Yagita∥, Pawel Muranski, Paul A. Antony, Nicholas P. Restifo, James P. Allison	635
20	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies breakdown → 2009 ·The Journal of Experimental Medicine ·Karl S. Peggs, Sergio A. Quezada, Cynthia A. Chambers, Alan J. Korman, James P. Allison	726

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact